Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596806 | 0.90 | TGFBR1 (0.66) | TGFBR1CYP3A4 | |
| SCHEMBL2596796 | 0.85 | TGFBR1 (0.69) | TGFBR1CYP3A4ACVR1BACVRL1ACVR1 | |
| SCHEMBL2596739 | 0.83 | TGFBR1 (0.56) | TGFBR1CYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL2598369 | 0.82 | TGFBR1 (0.51) | TGFBR1CYP3A4ACVR1BACVRL1ACVR1 | |
| SCHEMBL2596865 | 0.82 | TGFBR1 (0.80) | TGFBR1CYP3A4ACVR1BACVRL1ACVR1 | |
| SCHEMBL2596813 | 0.82 | TGFBR1 (0.51) | TGFBR1CYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL2596866 | 0.81 | TGFBR1 (0.53) | TGFBR1CYP3A4 | |
| SCHEMBL2596920 | 0.79 | TGFBR1 (0.53) | TGFBR1CYP3A4 | |
| SCHEMBL2596798 | 0.79 | TGFBR1 (0.68) | TGFBR1CYP3A4 | |
| SCHEMBL2596840 | 0.77 | TGFBR1 (0.58) | TGFBR1CYP3A4ACVR1BACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | TGFBR1 413/4885CYP3A4 65/4885PSEN1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.